Toxicology of Antidepressant Drugs

  • P. Thomann
  • R. Hess
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 55 / 1)


As many pharmacodynamic effects carry over from animals to man, many toxic effects may also be predicted from observations made in animals. However, some important toxic effects are not predictable from animal studies (WHO, 1966) and this limitation may apply particularly to drugs acting on the central nervous system, such as the antidepressants. Nevertheless, the recognition of species differences and similarities in responses is considered as an important means of predicting toxic effects in man. In the following, some degree of correlation is attempted by the comparison, whenever feasible, between toxicity in laboratory animals and adverse effects described in man, particularly in cases of acute intoxication. However, due to the differing amount of data that was available on various drugs and the widely varying experimental conditions employed, such a comparison may not always prove to be reliable.


Antidepressant Drug Monoamine Oxidase Inhibitor Daily Oral Dose Limb Deformity Myeloid Body 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abraham, R., Hendy, R., Grasso, P.: Formation of myeloid bodies in rat liver lysosomes after chloroquine administration. Exp. Mol. Pathol. 9, 212–229 (1968)PubMedGoogle Scholar
  2. Aeppli, L.: Teratologische Studien mit Imipramin an Ratte und Kaninchen. Ein Beitrag zur Planung und Interpretation teratologischer Untersuchungen unter Berücksichtigung von Biochemie und Toxikologie der Prüfsubstanz. Arzneim. Forsch. 19, 1617–1640 (1969)Google Scholar
  3. Allen, G.S., Rand, M.J.: Interaction between histamine and monoamine oxidase inhibitors. J. Pharm. Pharmacol. 21, 317–322 (1969)PubMedGoogle Scholar
  4. Ananth, J.: Side effects on fetus and infant of psychotropic drug use during pregnancy. Int. Pharmacopsychiatry 2, 246–260 (1976)Google Scholar
  5. Ashford, A., Ross, J.W.: Toxicity of depressant and antidepressant drugs in hyperthyroid mice. Br. Med. J. 1968/II, 217–218Google Scholar
  6. Attree, T., Sawyer, P., Turnbull, M.J.: Interaction between digoxin and tricyclic antidepressants in the rat. Eur. J. Pharmacol. 19, 294–296 (1972)PubMedGoogle Scholar
  7. Auclair, M.C., Guida, O., Lechat, P.: Analyse electrophysiologique des effects de l’imipramine sur la fibre myocardique ventriculaire. Arch. int. Pharmocodyn. 181, 218–231 (1969)Google Scholar
  8. Australian Drug Evaluation Committee: Tricyclic antidepressants and limb reduction deformities. Med. J. Aust. 1, 768–769 (1973)Google Scholar
  9. Bachmann, E., Zbinden, G.: Effect of antidepressant and neuroleptic drugs on mitochondrial function in rat heart and liver. 20th Congress of the European Society of Toxicology West Berlin, 25–28 June 1978Google Scholar
  10. Banister, P., Dafoe, C., Smith, E.S.O., Miller, J.: Possible teratogenicity of tricyclic antidepressants. Lancet 1972/I, 838Google Scholar
  11. Barson, A.J.: Malformed infant. Br. Med. J. 1972/II, 45Google Scholar
  12. Baum, T., Peters, J.R., Butz, F., Much, D.R.: Tricyclic antidepressants and cardiac conduction: changes in ventricular automaticity. Eur. J. Pharmacol. 39, 323–329 (1976)PubMedGoogle Scholar
  13. Beaubien, A.R., Carpentier, D.C., Mathieu, L.F., MacConaill, M., Hrdina, P.D.: Antagonism of imipramine poisoning by anticonvulsants in the rat. Toxicol. Appl. Pharmacol. 38, 1–6 (1976)PubMedGoogle Scholar
  14. Bickel, M.H.: Poisoning by tricyclic antidepressant drugs. Int. J. Clin. Pharmacol. 11, 145–176 (1975)Google Scholar
  15. Biggs, J.T., Spiker, D.G., Petit, J.M., Ziegler, V.E.: Tricyclic antidepressant overdose. JAMA 238, 135–138 (1977)PubMedGoogle Scholar
  16. Boissier, J.R., Simon, P., Witchitz, S.: Etude chez le Cobaye de la toxicité cardiaque de l’imipramine, de l’amitriptyline et de leurs dérivés monoadesméthyles. Therapie 20, 67–75 (1965)Google Scholar
  17. Bourke, G.M.: Antidepressant teratogenicity? Lancet 1974/I 98Google Scholar
  18. Brosnan, R.D., Busby, A.M., Holland, R.P.C.: Cases of overdosage with viloxazine hydrochloride. J. Int. Med. Res. 4, 83–85 (1976)PubMedGoogle Scholar
  19. Brown, T.C.K.: The use of sodium bicarbonate in the treatment of tricyclic antidepressant-in-duced arrhythmias. Anaesth. Intensive Care 1, 203–210 (1973)PubMedGoogle Scholar
  20. Brown, T.C.K.: Treatment of tricyclic antidepressant overdosage arrhythmias. Pediatrics 54, 386–387 (1974)PubMedGoogle Scholar
  21. Brown, T.C.K.: Tricyclic antidepressant overdosage: experimental studies on the management of circulatory complications. Clin. Toxicol. 9, 255–272 (1976a)PubMedGoogle Scholar
  22. Brown, T.C.K.: Sodium bicarbonate treatment for tricyclic antidepressant arrhythmias in children. Med. J. Aust. 2, 380–382 (1976b)PubMedGoogle Scholar
  23. Burkhardt, D., Raeder, E., Mueller, V., Imhof, P., Neubauer, H.: Cardiovascular effects of tricyclic and tetracyclic antidepressants. JAMA 239, 213–216 (1978)Google Scholar
  24. Burks, J.S., Walker, J.E., Rumack, B.H., Ott, J.E.: Tricyclic antidepressant poisoning. Reversal of coma, choreoathetosis, and myoclonus by physostigmine. JAMA 230, 1405–1407 (1974)PubMedGoogle Scholar
  25. Burrows, G.D., Vohra, J., Hunt, D., Sloman, J.G., Scoggins, B.A., Davies, B.: Cardiac effects of different tricyclic antidepressant drugs. Br. J. Psychiatry 129, 335–341 (1976)PubMedGoogle Scholar
  26. Cocco, G., Strozzi, C.: Interazioni cliniche fra farmaci cardioattivi ed antidepressivi. Clin. Ter. 76, 107–110(1976)Google Scholar
  27. Crombie, D.L., Pinsent, R.J., Fleming, G.: Imipramine in pregnancy. Br. Med. J. 1972/I, 745Google Scholar
  28. Davis, J.M., Bartlett, E., Termini, B.A.: Overdosage of psychotropic drugs: A review. Dis. Nerv. Syst. 29, 246–256 (1968)PubMedGoogle Scholar
  29. Dhumma Upakorn, P., Cobbin, L.B.: Cardiovascular toxicity of tricyclic antidepressant drugs. Clin. Exp. Pharmacol. Physiol. 2, 429–430 (1975)Google Scholar
  30. Di Carlo, R., Pagnini, G.: Comparative action of amitriptyline and butriptyline on skeletal development on the rat embryo. Teratology 4, 486 (1971)Google Scholar
  31. Dingell, J.V., Sulser, F., Gillette, J.R.: Species differences in the metabolism of imipramine and desmethylimipramine (DMI). J. Pharmacol, exp. Ther. 143, 14–22 (1964)Google Scholar
  32. Doggett, N.S., Reno, H., Spencer, P.S.J.: A comparison of the acute toxicity of some centrally acting drugs measured under crowded and uncrowded conditions. Toxicol. Appl. Pharmacol. 39, 141–148 (1977)PubMedGoogle Scholar
  33. Dumovic P., Burrows, G.D., Vohra, J., Davies, B., Scoggins, B.A.: The effect of tricyclic antidepressant drugs on the heart. Arch. Toxicol. 35, 255–262 (1976)PubMedGoogle Scholar
  34. Dumovic, P., Burrows, G.D., Vohra, J., Davies, B., Scoggins, B.A.: Cardiac effects of tricyclic antidepressants. Clin. Exp. Pharmacol. Physiol. 4, 207 (1977)Google Scholar
  35. Eckmann, F., Schwalb, H., Hanika, R.: Psychopharmaka und Veränderungen im Elektrokardiogramm. Pharmakopsychiat. Neuropsychopharmakol. 8, 57–58 (1975)Google Scholar
  36. Elonen, E., Mattila, M.J.: Comparison of tricyclic antidepressants as to their cardiotoxic action in conscious rabbits. Acta Pharmacol. Toxicol. 31, 64 (1972)Google Scholar
  37. Escande, M., Gayral, L., Goldberger, E., Jarrige, A., Kulik, J.: Accidents convulsif et modifications E.E.G. au cours des traitements par les antidépresseurs tricycliques. Encéphale 2, 133–151 (1976)PubMedGoogle Scholar
  38. Forfar, J.O., Nelson, M.M.: Epidemiology of drugs taken by pregnant women: drugs that may affect the fetus adversely. Clin. Pharmacol. Ther. 14, 632–642 (1973)PubMedGoogle Scholar
  39. Forrest, WA.: Maprotiline (Ludiomil) in depression: a report of a monitored release study of 10,000 patients in general practice. J. Int. Res. 5, 42–47 (1977)Google Scholar
  40. Fournier, E.: Intoxications par les antidepresseurs tricycliques. Therapie 28, 307–320 (1973)PubMedGoogle Scholar
  41. Fournier, P.E., Mellerio, F., Efthymion, M.L.: Etude expérimentale de l’intoxication aiguë par l’imipramine. Anesth. Analg. (Paris) 25, 263–269 (1966)Google Scholar
  42. Fowler, N.O., McCall, D., Chou, T., Homes, J.C., Hanenson, LB.: Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. Am. J. Cardiol. 37, 223–230 (1976)PubMedGoogle Scholar
  43. Freeman, R.: Limb deformities: possible association with drugs. Med. J. Aust. 1, 606–607 (1972)PubMedGoogle Scholar
  44. Freeman, J.W., Loughhead, M.G.: Beta blockade in the treatment of tricyclic antidepressant overdosage. Med. J. Aust. 1, 1233–1235 (1973)PubMedGoogle Scholar
  45. Freese, E., Sklarow, S., Freese, E.B.: DNA damage caused by antidepressant hydrazines and related drugs. Mutat. Res. 5, 343–348 (1968)PubMedGoogle Scholar
  46. Fuller, R.W., Snoddy, H.D.: Inhibition of serotonin uptake and the toxic interaction between meperidine and monoamine oxidase inhibitors. Toxicol. Appl. Pharmacol. 32, 129–134 (1975)PubMedGoogle Scholar
  47. Gessner, P.K.: Antagonism of the tranylcypromine-meperidine interaction by chlorpromazine in mice. Eur. J. Pharmacol. 22, 187–190 (1973)PubMedGoogle Scholar
  48. Gessner, P.K., Soble, A.G.: A study of the tranylcypromine-meperidine interaction: effects of p-chlorophenylalanine and 1–5-hydroxytryptophan. J. Pharmacol. Exp. Ther. 186. 276–287 (1973)PubMedGoogle Scholar
  49. Gessner, P.K., Soble, A.G., Buffalo, N.Y.: Antagonism by p-chlorophenylalanine of late tranylcypromine toxicity. J. Pharm. Pharmacol. 24, 825–827 (1972)PubMedGoogle Scholar
  50. Gessner, P.K., Clarke, C.C., Adler, M.: The effect of low environmental temperature on the tranylcypromine-meperidine interaction in mice. J. Pharmacol. Exp. Ther. 189, 90–96 (1974)PubMedGoogle Scholar
  51. Glisson, S.N., Fajardo, L., El-Etr, A.A.: Amitriptyline therapy increases electrocardiographic changes during reversal of neuromuscular blockade. Anesth. Analg. (Cleve) 57, 77–83 (1978)Google Scholar
  52. Goel, K.M., Shanks, R.A.: Amitriptyline and imipramine poisoning in children. Br. Med. J. 1974/I, 261–263Google Scholar
  53. Goldberg, R.S., Thornton, W.E.: Combined tricyclic-MAOI therapy for refractory depression: a review, with guidelines for appropriate usage. J. Clin. Pharmacol. 18, 143–147 (1978)PubMedGoogle Scholar
  54. Goodman, L.S., Gilman, A.: The pharmacological basis of therapeutics, New York: Macmillan 5th ed. 1975Google Scholar
  55. Greenberg, G., Anman, W.H.W., Weatherall, J.A.C., Adelstein, A.M., Haskey, J.C.: Maternal drug histories and congenital abnormalities. Br. Med. J. 1977/II, 853–856Google Scholar
  56. Hallstrom, C., Gifford, L.: Antidepressant blood levels in acute overdose. Postgrad. Med. J. 52, 687–688 (1976)PubMedGoogle Scholar
  57. Hamilton, M., Mahapatra, S.B.: Antidepressive drugs: side effects of drugs. Amsterdam: Ex-cerpta Medica, 1972Google Scholar
  58. Harper, K.H., Palmer, A.K., Davies, R.E.: Effect of imipramine upon the pregnancy of laboratory animals. Arzneim. Forsch. 15, 1218–1221 (1965)Google Scholar
  59. Heggtveit, H.A., Grice, H.C., Wiberg, G.S.: Cardiac necrosis induced by a monoamine oxidase inhibitor (tranylcypromine). Am. J. Pathol. 50, 2a–3a (1967)Google Scholar
  60. Hendrickx, A.G.: Teratologic evaluation of imipramine hydrochloride in bonnet (Macaca radiata) and rhesus monkeys (Macaca mulatta). Teratology 11, 219–222 (1975)PubMedGoogle Scholar
  61. Hess, R., Diener, R.M., Fritz, H., Pericin, C., Heywood, R., Newman, A.J., Rivett, K.F.: Tos-sità ed effetti sulla riproduzioni nell’animale del nuovo farmaco antidepressivo maprotilina (Ludiomil). Boll. Chim. Farm. 112, 782–791 (1973)PubMedGoogle Scholar
  62. Hollinger, P.C., Klawans, H.L.: Reversal of tricyclic-overdosage-induced central anticholinergic syndrome by physostigmine. Am. J. Psychiatry 133, 1018–1023 (1976)Google Scholar
  63. Hollister, L.E.: Adverse reactions to psychotherapeutic drugs: drug treatment of mental disorders. Simpson, L. L. (ed.), pp. 267–288. New York: Raven 1976Google Scholar
  64. Hruban, Z., Slesers, A., Hopkins, E.: Drug-induced and naturally occurring myeloid bodies. Lab. Invest. 27, 62–70 (1972)PubMedGoogle Scholar
  65. Hurwitz, A., Azarnoff, D.L.: Clinical principles of drug interactions in the adult patient. Ann. N.Y. Acad. Sci. 281, 98–105 (1976)PubMedGoogle Scholar
  66. Idänpään-Heikkila, J., Saxen, L.: Possible teratogenicity of imipramine/chloropyramine. Lancet 1973/II, 282–284Google Scholar
  67. Jacobs, D.: Imipramine (Tofranil). S. Afr. Med. J. 46, 1023 (1972)PubMedGoogle Scholar
  68. Janson, P.A., Brooks Watt, J., Hermos, J.A.: Doxepin overdose: success with physostigmine and failure with neostigmine in reversing toxicity. JAMA 237, 2632–2633 (1977)PubMedGoogle Scholar
  69. Jelinek, V., Zikmund, E., Reichlova, R.: L’influence de quelques médicaments psychotropes sur le développement du foetus chez le rat. Therapie 22, 1429–1433 (1967)PubMedGoogle Scholar
  70. Johnson, G.F.S.: Clinical use of anti depressant drugs. Curr. Ther. 17, 33–34, 37, 40–41 (1976a)Google Scholar
  71. Johnson, P.B.: Physostigmine in tricyclic antidepressant overdose. JACEP 5, 443–445 (1976b)PubMedGoogle Scholar
  72. Jukes, A.M.: Maprotiline (Ludiomil): side-effects and overdosage. J. Int. Res. 3, 126 (1975)Google Scholar
  73. Karabelnik, D., Zbinden, G., Baumgartner, E.: Drug-induced foam cell reactions in rats. I. Histopathologic and cytochemical observations after treatment with chlorphentermine, RMI 10 393 and Ro 4–4318. Toxicol. Appl. Pharmacol. 27, 395–407 (1974)PubMedGoogle Scholar
  74. Khan, I., Azam, A.: Teratogenic activity of trifluoperazine, amitriptyline, ethionamide, and thalidomide in pregnant rabbits and mice. Proc. Eur. Soc. Study Drug Toxic 10, 235–242 (1969)Google Scholar
  75. Kuennsberg, E.V., Knox, J.D.E.: Imipramine in pregnancy. Br. Med. J. 1972/II, 292Google Scholar
  76. Lal, H., Brown, R.M.: Enhanced toxicity of imipramine and desimipramine in aggregated mice. J. Pharm. Pharmacol. 20, 581–582 (1968)PubMedGoogle Scholar
  77. Lamarche, M., Royer, R., Weiller, M., Denis, P.: Etude pharmacodynamique de la toxicité cardiaque de l’amitriptyline. Therapie 21, 59–71 (1966)Google Scholar
  78. Lapin, LP., Samsonova, M.L.: Comparison of pharmacological activity and toxicity of the antidepressants — nialamide, phenelzine and iproniazid. Farmacol. Toksikol. 32, 526–530 (1969)Google Scholar
  79. Larsen, V.: The teratogenic effects of thalidomide, imipramine HCl and imipramine-N-oxide HCl on white Danish rabbits. Acta Pharmacol. 20, 186–200 (1963)Google Scholar
  80. Lee, R.L., Spencer, P.S.J.: The effect of clomipramine and other amine-uptake inhibitors on morphine analgesia in laboratory animals. Postgrad. Med. J. 53, 53–61 (1977)PubMedGoogle Scholar
  81. Lippmann, S., Moskovitz, R., O’Tuama, L.: Tricyclic-induced myoclonus. Am. J. Psychiatry 134, 90–91 (1977)PubMedGoogle Scholar
  82. Luellmann, H., Luellmann-Rauch, R., Wassermann, O.: Arzneimittelinduzierte Phospholipid-speicherkrankheit. Dtsch. Med. Wochenschr. 98, 1616–1625 (1973)Google Scholar
  83. Luellmann, H., Luellmann-Rauch, R., Wassermann, O.: Drug-induced phospholipidosis. CRC Crit. Rev. Toxicol. 4, 185–218 (1975)Google Scholar
  84. Männistö, P., Nikki, P., Rissanen, A.: The toxicity of two MAO inhibitors combined with 5-HTP or L-DOPA in anaesthetized mice. Acta Pharmacol. Toxicol. 29, 441–448 (1971)Google Scholar
  85. Manoguerra, A.S., Weaver, L.C.: Poisoning with tricyclic antidepressant drugs. Clin. Toxicol. 2, 149–158 (1977)Google Scholar
  86. Maxwell, D.R.: Combining the antidepressant drugs. Lancet 1965/II, 904–905Google Scholar
  87. McBride, W.G.: Limb deformities associated with iminodibenzyl hydrochloride. Med. J. Aust. 1, 492 (1972)PubMedGoogle Scholar
  88. Meyers, D.B., Kanyuck, D.O., Anderson, R.C.: Effect of chronic nortriptyline pretreatment on the acute toxicity of various medicinal agents in rats. J. Pharm. Sci. 55, 1317–1318 (1966a)PubMedGoogle Scholar
  89. Meyers, D.B., Small, R.M., Anderson, R.C.: Toxicology of nortriptyline hydrochloride. Toxicol. Appl. Pharmacol. 9, 152–159 (1966b)PubMedGoogle Scholar
  90. Milner, G.: The effect of antidepressants and “tranquillizers” on the response of mice to ethanol. Br. J. Pharmacol. 34, 370–376 (1968)PubMedGoogle Scholar
  91. Moeschlin, S.: Klinik und Therapie der Vergiftungen. Stuttgart: Thieme 1972Google Scholar
  92. Morrow, A.W., Pitt, D.B., Wilkins, G.D.: Limb deformities associated with iminodibenzyl hydrochloride. Med. J. Aust. 1, 658–659 (1972)PubMedGoogle Scholar
  93. Munoz, R.A.: Treatment of tricyclic intoxication. Am. J. Psychiatry 133, 1085–1087 (1976)PubMedGoogle Scholar
  94. Noble, J., Matthew, H.: Acute poisoning by tricyclic antidepressants: clinical features and management of 100 patients. Clin. Toxicol. 2, 403–421 (1969)Google Scholar
  95. Nymark, M., Rasmussen, J.: Effect of certain drugs upon amitriptyline induced electrocardiographic changes. Acta Pharmacol. Toxicol. 24, 148–156 (1966)Google Scholar
  96. O’Dea, K., Rand, J.: Interaction between amphetamine and monoamine oxidase inhibitors. Eur. Pharm. J. 6, 115–120 (1969)Google Scholar
  97. Panisset, J.C., Boivin, P., Napke, E., Murphy, J.B.: Effect of tranylcypromine on the blood pressure response of tyramine. Nature 206, 311–312 (1965)PubMedGoogle Scholar
  98. Paton, A: Diseases of the alimentary system. Drug jaundice. Br. Med. J. 2, 1126–1127 (1967a)Google Scholar
  99. Paton, A.: Diseases of the alimentary system. Gastrointestinal reactions to drugs. Br. Med. J. 2, 1179–1180 (1976b)PubMedGoogle Scholar
  100. Peckham, C.H., King, R.W.: A study of intercurrent conditions observed during pregnancy. Am. J. Obstet. Gynecol. 87, 609–624 (1963)PubMedGoogle Scholar
  101. Petit, J.M., Biggs, J.T.: Tricyclic antidepressant overdoses in adolescent patients. Pediatrics 59, 283–287 (1977)PubMedGoogle Scholar
  102. Petit, J.M., Spiker, D.G., Biggs, J.T.: Psychiatric diagnosis and tricyclic plasma levels in 36 hospitalized overdose patients. J. Nerv. Ment. Dis. 163, 289–293 (1976)PubMedGoogle Scholar
  103. Petit, J.M., Spiker, D.G., Ruwitch, J.F., Ziegler, V.E., Weiss, A.N., Biggs, J.T.: Tricyclic antidepressant plasma levels and adverse effects after overdose. Clin. Pharmacol. Ther. 21, 47–51 (1977)PubMedGoogle Scholar
  104. Physicians Desk Reference (PDR): Oradell: Medical Economics 1973Google Scholar
  105. Pluvinage, R.: La protriptyline, antidépresseur tricycline majeur. Etude clinique et thérapeutique. Therapie 24, 273 282 (1969)Google Scholar
  106. Poulson, E., Robson, J.M.: The effect of amine oxidase inhibitors on pregnancy. J. Endocrinol. 27, 147–152 (1963)PubMedGoogle Scholar
  107. Poulson, E., Robson, J.M.: Effect of phenelzine and some related compounds on pregnancy and on sexual development. J. Endocrinol. 30, 205–215 (1964)PubMedGoogle Scholar
  108. Rachelefsky, G.S., Flynt, J.W., Ebbin, A.J., Wilson, M.G.: Possible teratogenicity of tricyclic antidepressants. Lancet 1872/I, 838–839Google Scholar
  109. Rauws, A.G., Oiling, M.: Treatment of experimental imipramine and desipramine poisoning in the rat. Arch. Toxicol. 35, 97–106 (1976)PubMedGoogle Scholar
  110. Reid, W.H., Blouin, P., Schermer, M.: A review of psychotropic medications and the glaucomas. Int. Pharmacopsychiatry 11,163–174 (1974)Google Scholar
  111. Report From Boston Collaborative Drug Surveillance Program: Adverse reactions to the tricyclic-antidepressant drugs. Lancet 1972/I, 529–531Google Scholar
  112. Robson, J.M., Sullivan, F.M.: The production of foetal abnormalities in rabbits by imipramine. Lancet 1963/I, 638–639Google Scholar
  113. Rogers, K.J., Thornton, J.A.: Pharmacological observations on the interaction between monoamine oxidase inhibitors and narcotic analgesics in animals. Br. J. Anaesth. 40, 146 (1968)Google Scholar
  114. Rogers, K.J., Thornton, J.A.: The interaction between monoamine oxidase inhibitors and narcotic analgesics in mice. Br. J. Pharmacol. 36, 470–480 (1969)PubMedGoogle Scholar
  115. Rossi, G.V.: Pharmacology of tricyclic antidepressants. A review. Am. J. Pharm. 148, 37–45 (1976)PubMedGoogle Scholar
  116. Schaerer, K.: Toxizitätsstudien mit Amitriptylin. Therapeutische Richtlinien aus experimentellen Untersuchungen. Schweiz. Med. Wochenschr. 95, 173–176 (1965)PubMedGoogle Scholar
  117. Schardein, J.L.: Drugs as teratogens. Cleveland (Ohio): CRC Press 1976Google Scholar
  118. Sedal, L., Korman, M.G., Williams, P.O., Mushin, G.: Overdosage of tricyclic antidepressants. A report of two deaths and a prospective study of 24 patients. Med. J. Aust. 2, 74–79 (1972)PubMedGoogle Scholar
  119. Serafimovski, N., Thorball, N., Asmussen, I., Lunding, M.: Tricyclic antidepressive poisoning with special reference to cardiac complications. Acta Anaesth. Scand. 57, 55–63 (1975)Google Scholar
  120. Shikata, T., Kanetaka, T., Endo, Y., Nagashima, K.: Drug-induced generalized phospholipi-dosis. Acta Pathol. Jpn. 22, 517–531 (1972)PubMedGoogle Scholar
  121. Shimomura, K., Hashimoto, M., Honda, F.: A fatal hyperpyrexia caused by tranylcypromine in LiCl-pretreated rats. Jap. J. Pharmacol. 27, 124 P (1977)Google Scholar
  122. Sim, M.: Imipramine and pregnancy. Br. Med. J. 1972/II, 45Google Scholar
  123. Sinclair, J.G.: Ethoheptazine-monoamine oxidase inhibitor interaction in rabbits. Can. J. Physiol. Pharmacol. 50, 923–926 (1972)PubMedGoogle Scholar
  124. Singer, G., Coyle, I.R.: The effect of imipramine administered before and during pregnancy on litter size in the rat. Psychopharmacologia 32, 337–342 (1973)PubMedGoogle Scholar
  125. Slovis, T.L., Ott, J.E., Teitelbaum, D.T., Lipscomb, W.: Physostigmine therapy in acute tricyclic antidepressant poisoning. Clinical Toxicology, 4, 451–459 (1971)PubMedGoogle Scholar
  126. Sokol, G.H., Maikel, R.P.: Toxic interactions of d-amphetamine and tricyclic antidepressants in mice. Res. Commun. Chem. Pathol. Pharmacol. 3, 513–521 (1972)PubMedGoogle Scholar
  127. Soulairac, A., Baron, J.B., Geier, S., Mijolla, A. de, Aymard, N.: Etude clinique et experimentale de l’amitriptyline sur la vascularisation retinienne des sujets atheromateux. Ann. Med. Psychol. 1, 208–216 (1965)Google Scholar
  128. Spiker, D.G., Biggs, J.T.: Tricyclic antidepressants. Prolonged plasma levels after overdose. J. Am. Med. Assoc. 236, 1711–1712 (1976)Google Scholar
  129. Spiker, G.D., Weiss, N.A., Chang, S.S., Ruwitch, J.F., Biggs, J.T.: Tricyclic antidepressant overdose: Clinical presentation and plasma levels. Clinical Pharm. Therap. 18, 539–546 (1975)Google Scholar
  130. Staeubli, W., Schweizer, W., Suter, J., Hess, R.: Ultrastructure and biochemical study of the actions of benzoctamine and maprotiline on the rat liver. Agents Actions 4, 391–403 (1974)Google Scholar
  131. Staeubli, W., Schweizer, W., Suter.: Some properties of myeloid bodies induced in rat liver by an antidepressant drug (maprotiline). Exp. Mol. Pathol. 28, 177–195 (1978)Google Scholar
  132. Stenger, E.G., Aeppli, L., Fratta, I.: Zur Frage der keimschädigenden Wirkung von N-(α-Di-methylaminopropyl)-iminodibenzyl-HCl am Tier. Arzneim. Forsch. 15, 1222–1224 (1965)Google Scholar
  133. Stokes, G.S.: Drug-induced hypertension. Pathogenesis and management. Drugs 12, 222–230 (1976)PubMedGoogle Scholar
  134. Swiss Academy of Medical Sciences: Evaluation of drugs and other chemical agents for teratogenicity. Joint report of the Expert Committee on Teratogenicity Testing and Evaluation. Bull. Schweiz. Akad. Med. Wiss. 30, 1–62 (1974)Google Scholar
  135. Tanaka, H., Furusato, M., Takasaki, S., Watanabe, M., Hattori, Y.: Morphological and biochemical alteration in the rat liver induced by maprotiline. Acta Pathol. Jpn. 25, 413–437 (1975)PubMedGoogle Scholar
  136. Tobis, J., Das, B.N.: Cardiac complications in amitriptyline poisoning. JAMA, 235, 1474–1476 (1976)PubMedGoogle Scholar
  137. Theiss, E., Hummler, H., Lengsfeld, H., Staiger, G.R., Tranzer, J.P.: Lipidspeicherung bei Versuchstieren nach Verabreichung trizyklischer Amine. Schweiz. Med. Wochenschr. 103, 424 (1973)Google Scholar
  138. Thomann, P.: Toxicology of Tofranil: Tofranil, pp. 145–159. Bern: Stämpfli 1970Google Scholar
  139. Thorstrand, C.: Cardiovascular effects of poisoning by hypnotic and tricyclic antidepressant drugs. Acta Med. Scand. 583, 1–34 (1975)Google Scholar
  140. Thorstrand, C.: Clinical features in poisonings by tricyclic antidepressants with special reference to the ECG. Acta Med. Scand. 199, 337–344 (1976)PubMedGoogle Scholar
  141. Tofanetti, O., Albiero, L., Galatulas, I., Genovese, E.: Enhancement of propoxyphene-induced analgesia by doxepin. Psychopharmacology 51, 213–215 (1977)PubMedGoogle Scholar
  142. Torchiana, M.L., Wenger, H.C., Lagerquist, B., Morgan, G.M., Stone, C.A.: Pharmacological antagonism of the toxic manifestations of amitriptyline and protriptyline in dogs. Toxicol. Appl. Pharmacol. 21, 383–389 (1972)PubMedGoogle Scholar
  143. Toth, B.: Tumorigenicity of β-phenylethylhydrazine sulfate in mice. Cancer Res. 36, 917–921 (1976)PubMedGoogle Scholar
  144. Tuchmann-Duplessis, H.: Drug effects on the fetus. Monographs on drugs, Vol.2. New York, London, Hongkong, Mexico, Sidney, Auckland: Adis Press 1975Google Scholar
  145. Ueki, S., Fujiwara, M., Inoue, K.: Behavioral effects of maprotyline (Ciba 34 376-Ba). A new antidepressant. Jpn. J. Pharmacol. 24, [Suppl. 55] (1974)Google Scholar
  146. Vance, M.A., Ross, S.M., Millington, W.R., Blumberg, J.B.: Potentiation of tricyclic antidepressant toxicity by physostigmine in mice. Clin. Toxicol. 11, 413–421 (1977)PubMedGoogle Scholar
  147. Vohra, J.K.: Cardiovascular abnormalities following tricyclic antidepressant drug overdosage. Drugs 7, 323–325 (1974)PubMedGoogle Scholar
  148. Vohra, J., Burrows, G., Hunt, D., Sloman, G.: The effect of toxic and therapeutic doses of tricyclic antidepressant drugs on intracardiac conduction. Eur. J. Cardiol. Excerpta Medica 3, 219–227 (1975)Google Scholar
  149. Volk, B.W., Adachi, M., Schneck, L.: The gangliosidoses. Hum. Pathol. 6, 555–569 (1975)PubMedGoogle Scholar
  150. Winter, D.: Toxizitätsveränderung neurotroper Pharmaka bei Versuchstieren mit experimentell hervorgerufener Hyperthyreoidie. Med. Pharmacol. Exp. 14, 391–394 (1966)Google Scholar
  151. Wood, C.A., Brown, J.R., Coleman, J.H., Evans, W.E.: Management of tricyclic antidepressant toxicities. Dis. Nerv. Syst. 37, 459–461 (1976)PubMedGoogle Scholar
  152. WHO; Report of a WHO Scientific Group: Principles for pre-clinical testing of drug safety. WHO Technical Report Series No. 341 (1966)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • P. Thomann
  • R. Hess

There are no affiliations available

Personalised recommendations